

In the claims:

Please amend claims 1, 2, 3, 5, 6, 11-13, 15 and 17-19 without prejudice, as indicated below.

1. (Currently Amended) A method of inhibiting interleukin-1 alpha (IL-1 α) release from a cell, said method comprising administering an effective amount of an IL-1 α release inhibitor to said cell, thereby inhibiting IL-1 α release from said cell.
2. (Currently Amended) The method of claim 1, wherein said release is stress-induced, and further wherein said IL-1 α release inhibitor is selected from the group consisting of a copper chelator and a S100A13, or a fragment thereof.
3. (Currently Amended) The method of claim 3, wherein said S100A13 fragment is a S100A13 Δ BR truncated protein.
4. (Original) The method of claim 4, wherein said copper chelator is tetrathiomolybdate (TTM).
5. (Currently Amended) A method of treating a condition mediated by stress-induced release of IL-1 α from a cell, said method comprising administering an effective amount of a copper chelator to said cell, thereby treating said condition.
6. (Currently Amended) A method of inhibiting neointima formation following vessel injury in a mammal, said method comprising administering to said mammal an IL-1 α release inhibiting amount of a copper chelator, thereby inhibiting said neointima formation.
7. (Original) A method of inhibiting macrophage infiltration following vessel injury in a mammal, said method comprising administering to said mammal an effective amount of a copper chelator, thereby inhibiting said macrophage infiltration.
8. (Original) The method of claim 7, wherein said macrophage infiltration is

associated with inflammation.

9. (Original) A method of inhibiting cell proliferation associated with arterial wall injury, said method comprising administering an effective amount of a copper chelator to said mammal, thereby inhibiting said cell proliferation.

10. (Original) The method of claim 9, wherein said cell is a vascular smooth muscle cell and further wherein said copper chelator is TTM and said injury is caused by balloon angioplasty.

11. (Currently Amended) A method of inhibiting secretion of extracellular matrix following arterial wall injury in a mammal, said method comprising inhibiting non-traditional export of at least one of FGF-1 and IL-1 α from a cell at the site of said injury, and further wherein said export is inhibited by administering an effective amount of a copper chelator to said mammal, thereby inhibiting said secretion of extracellular matrix in said mammal.

12. (Currently Amended) A method of inhibiting neointimal thickening associated with arterial wall injury in a mammal, said method comprising inhibiting non-traditional export of at least one of FGF-1 and IL-1 α from a cell at the site of said injury, and further wherein said export is inhibited by administering an effective amount of a copper chelator to said mammal, thereby inhibiting said neointimal thickening in said mammal.

13. (Currently Amended) A method of inhibiting adventitial angiogenesis associated with arterial wall injury in a mammal, said method comprising inhibiting non-traditional export of at least one of FGF-1 and IL-1 α from a cell at the site of said injury, and further wherein said export is inhibited by administering an effective amount of a copper chelator to said mammal, thereby inhibiting said adventitial angiogenesis in said mammal.

14. (Original) A method of identifying a compound useful for inhibiting adventitial angiogenesis associated with arterial wall injury in a mammal, said method

comprising contacting a cell with a compound and comparing the level of release of a leader-less pro-inflammatory cytokine by said cell in response to temperature stress with the level of release of said cytokine from an otherwise identical cell not contacted with said compound in response to said temperature stress, wherein a decrease in said level of release of said leader-less pro-inflammatory cytokine by said contacted with said compound with said level of release of said cytokine from said otherwise identical cell not contacted with said compound is an indication that said compound inhibits said angiogenesis, thereby identifying a compound useful for inhibiting adventitial angiogenesis associated with arterial wall injury in a mammal.

15. (Currently Amended) The method of claim 14, wherein said leader-less pro-inflammatory cytokine is selected from the group consisting of FGF-1 and IL-1 α .

16. (Original) A compound identified by the method of claim 14.

17. (Currently Amended) A kit for inhibiting ~~release~~ release of IL-1 α from a cell, said kit comprising an effective amount of an IL-1 α release inhibitor, said kit further comprising an applicator and an instructional material for the use thereof.

18. (Currently Amended) A kit for treating a condition mediated by stress-induced release of IL-1 α from a cell, said kit comprising an effective amount of a copper chelator, said kit further comprising an applicator and an instructional material for the use thereof.

19. (Currently Amended) A kit for inhibiting neointima formation following vessel injury in a mammal, said kit comprising an IL-1 α release inhibiting amount of a copper chelator, said kit further comprising an applicator and an instructional material for the use thereof.

20. A kit for inhibiting restenosis following vessel injury in a mammal, said kit comprising an effective amount of a copper chelator, said kit further comprising an applicator and an instructional material for the use thereof.